CytoAgents | Ben Franklin 4 PA

News

Ben Franklin Technology Partners has earned international acclaim as the gold standard in technology-based economic development. The risks associated with underfunding the centers are clear.

NextPittsburgh: Innovation Works reports $372 million invested in Pittsburgh tech startups this year

Ben Franklin 4 PA

Mar 25, 20213 min read

NextPittsburgh: Innovation Works reports $372 million invested in Pittsburgh tech startups this year

When the pandemic first shut down much of the country, Innovation Works launched a Covid Resiliency Fund to help vulnerable early-stage tech

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

Ben Franklin 4 PA

Dec 10, 20203 min read

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

CytoAgents, a Ben Franklin Technology Partners company, has begun its Phase 1 clinical trial for COVID-19 treatment.